Paper Details

  1. Home
  2. Paper Details

COVID-19-related arrhythmias and the possible effects of ranolazine.

Author: AbaciogluNurettin, ChukwunyereUgochukwu, SehirliAhmet Ozer

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ranolazine is a drug used to treat angina and may have antiarrhythmic effects. This review examines the potential for ranolazine to treat arrhythmias associated with COVID-19.
Paper Details　
Original Abstract of the Article :
The COVID-19 pandemic has become a burden to the global healthcare community. Despite the severity of the complications associated with COVID-19, no antiviral agent is yet available for the treatment of this disease. Several studies have reported arrhythmias as one of the numerous manifestations ass...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890340/

データ提供：米国国立医学図書館（NLM）

COVID-19 and Arrhythmias: Ranolazine as a Potential Treatment Option

The COVID-19 pandemic has brought about a myriad of challenges, including the emergence of cardiac complications, such as arrhythmias. This article explores the potential antiarrhythmic effects of ranolazine in the management of COVID-19-related arrhythmias. Ranolazine, a second-line drug approved for the treatment of chronic stable angina pectoris, is known for its beneficial cardiac effects without significant hemodynamic impact. The authors propose that ranolazine's reduced side effects could make it a valuable tool for managing arrhythmias in COVID-19 patients, especially considering the potential risks associated with other antiarrhythmic medications.

Ranolazine: A Potential Oasis in the Desert of COVID-19 Arrhythmias

This article, like a desert explorer seeking a source of relief, examines the potential of ranolazine in managing COVID-19-related arrhythmias. The authors highlight the unique properties of ranolazine, its ability to modulate sodium, potassium, and calcium channels, and suppress cytokine expression, suggesting its potential efficacy in treating arrhythmias while minimizing adverse effects. This could offer a valuable alternative for COVID-19 patients who may not tolerate other antiarrhythmic medications.

Navigating the Complexities of COVID-19: Staying Informed and Prepared

COVID-19, like a challenging desert journey, can present unexpected challenges. This article sheds light on the potential of ranolazine in addressing one such challenge, COVID-19-related arrhythmias. It emphasizes the importance of staying informed about the latest advancements in medical research and seeking expert guidance from healthcare professionals.

Dr.Camel's Conclusion

This article, like a compass guiding a lost traveler, explores the potential of ranolazine in addressing the challenges posed by COVID-19-related arrhythmias. Remember, like navigating a desert, managing your health requires staying informed, seeking expert guidance, and embracing new possibilities for treatment.

Date :
  1. Date Completed 2021-04-15
  2. Date Revised 2022-12-21
Further Info :

Pubmed ID

33636586

DOI: Digital Object Identifier

PMC7890340

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.